Compare GCO & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCO | VOGX |
|---|---|---|
| Founded | 1924 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.8M | 456.5M |
| IPO Year | 1994 | 2026 |
| Metric | GCO | VOGX |
|---|---|---|
| Price | $33.41 | $32.13 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $33.00 | N/A |
| AVG Volume (30 Days) | 193.7K | ★ 289.4K |
| Earning Date | 06-03-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 171.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,606,898,000.00 | N/A |
| Revenue This Year | $0.78 | N/A |
| Revenue Next Year | $2.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.71 | N/A |
| 52 Week Low | $21.93 | $14.80 |
| 52 Week High | $43.60 | $35.50 |
| Indicator | GCO | VOGX |
|---|---|---|
| Relative Strength Index (RSI) | 37.65 | 92.71 |
| Support Level | $31.11 | N/A |
| Resistance Level | $36.81 | $35.50 |
| Average True Range (ATR) | 1.27 | 5.25 |
| MACD | -0.33 | 1.57 |
| Stochastic Oscillator | 6.82 | 84.18 |
Genesco Inc sells footwear, headwear, sports apparel, and accessories. It has four reportable business segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass. The brands of the company are: Journeys; Journeys Kidz; Little Burgundy; Schuh; Johnston & Murphy; and Genesco Brands Group.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.